Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 7/20 | 0.46 |
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30280440 | 1.00 | SGMS2 (0.46) | SGMS2ELANEALDH1A1KDM4ENPC1 | |
| SCHEMBL13053003 | 0.77 | SGMS2 (0.51) | SGMS2ELANEALDH1A1KDM4ENPC1 | |
| SCHEMBL13052972 | 0.77 | SGMS2 (0.51) | SGMS2ELANEALDH1A1KDM4ENPC1 | |
| SCHEMBL1074019 | 0.75 | ALDH1A1 (0.41) | SGMS2ALDH1A1KDM4ENPC1TP53 | |
| SCHEMBL5140187 | 0.75 | ALDH1A1 (0.41) | SGMS2ALDH1A1KDM4ENPC1TP53 | |
| SCHEMBL29657370 | 0.75 | ALDH1A1 (0.41) | SGMS2ALDH1A1KDM4ENPC1TP53 | |
| SCHEMBL845891 | 0.75 | ALDH1A1 (0.41) | SGMS2ALDH1A1KDM4ENPC1TP53 | |
| SCHEMBL10278989 | 0.75 | ALDH1A1 (0.41) | SGMS2ALDH1A1KDM4ENPC1TP53 | |
| SCHEMBL30988533 | 0.75 | ELANE (0.44) | SGMS2ELANEALDH1A1KDM4ENPC1 | |
| SCHEMBL30648204 | 0.75 | ALDH1A1 (0.41) | SGMS2ALDH1A1KDM4ENPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | CHECKMATE THERAPEUTICS INC. | 2023-10-24 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220386614-A1 | OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | NIHON NOHYAKU CO., LTD. (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11245078-B2 | Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
| US-11078195-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | CHECKMATE THERAPEUTICS INC. | 2021-08-03 | — | — | US | disclosed |
| WO-2021147940-A1 | PD-1/PD-L1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海华汇拓医药科技有限公司 | 2021-07-29 | — | — | WO | disclosed |
| US-5536702-A | (2-imidazolin-2-yl) fused heteropyridine compounds and use of said compounds as herbicidal agents | AMERICAN CYANAMID CO. (US) | 1996-07-16 | — | — | US | disclosed |
| US-5536839-A | HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5534483-A | (2-imidazolin-2-yl) fused heteropyridine compounds intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534485-A | (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534484-A | (2-imidazolin-2-yl)fused heteropyridine compounds intermediates for the preparation of and use of said compounds and herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5532207-A | CONTROL OF MONO- AND DI-COTYLEDONOUS ANNUAL, PERENNIAL AND AQUATIC PLANTS; PRE- AND POST-EMERGENCE USE | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5510319-A | PYRROLO-2,3-B-PYRIDINYL DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-5252538-A | (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0227932-B1 | NOVEL FUSED PYRIDINE COMPOUNDS, INTERMEDIATES FOR THE PREPARATION OF, AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | AMERICAN CYANAMID COMPANY (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0227932-A1 | Novel fused pyridine compounds, intermediates for the preparation of, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | SGMS2 3659/4885ELANE 3545/4885ALDH1A1 3543/4885 |
| US-20220386614-A1 | OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | BROX, CYP51A1, TBCD | SGMS2 3315/4885ELANE 3612/4885ALDH1A1 1832/4885 |
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | AHR, ORAI3, WNT3 | SGMS2 4400/4885ELANE 3131/4885ALDH1A1 1797/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | SGMS2 3207/4885ELANE 2997/4885ALDH1A1 2468/4885 |
| US-11078195-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | NAMPT, NAPRT, NNT | SGMS2 1634/4885ELANE 2961/4885ALDH1A1 1903/4885 |
| US-11245078-B2 | Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity | HSPA9, CASP9, PARP9 | SGMS2 3329/4885ELANE 1642/4885ALDH1A1 584/4885 |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | NAMPT, NAPRT, NNT | SGMS2 1634/4885ELANE 2961/4885ALDH1A1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.